Implementation of an Interleukin-2 National Registry: An opportunity to improve cancer outcomes

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Wong, Michael K ^a   Kaufman, Howard L ^b   Daniels, Gregory A ^c   McDermott, David F ^d   Aung, Sandra ^e   Lowder, James N ^e   Morse, Michael A ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Prometheus Laboratories Inc   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer; Cure; Immunotherapy; Interleukin 2; Melanoma; Metastatic; Registry; Renal cell carcinoma

Indexed keywords

INTERLEUKIN 2;

CANCER IMMUNOTHERAPY; CANCER REGISTRY; DATA BASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; NEOPLASM; NOTE; PRIORITY JOURNAL; SURVIVAL;

EID: 84977111945     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/2051-1426-2-20     Document Type: Note

References (17)

1. National Cancer Database (NCDB). [http://www.facs.org/cancer/ncdb/index.html].
2. Surveillance, Epidemiology, and End Results (SEER). [http://seer.cancer.gov/about/factsheets/SEER_brochure.pdf].
3. Horowitz MM. Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?. Best Pract Res Clin Haematol 2012, 25:483-486.
4. Center for International Bone Marrow Transplant Registry (CIBMTR). [http://www.cibmtr.org].
5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
6. Alimohamed N, Lee JL, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Tantravahi S, Kollmannsberger C, North S, Rini BI, Choueiri TK, Heng DY. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma [abstract]. Clin Genitourin Cancer 2013, http://dx.doi.org/10.1016/j.clgc.2013.12.003.
7. Harshman LC, Xie W, Bjarnason GA, Knox JJ, MacKenzie M, Wood L, Srinivas S, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012, 13:927-935.
8. Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Neithammer A, Lu DR, Hariharan S, Motzer RJ. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2014, 32:760-767.
9. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A. RECORD-1 Study group: efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
10. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
11. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, Pittman KB, Sabbatini R, Rha SY, Flaig TW, Page RD, Bavbek SE, Beck JT, Patel PM, Schiff E, Vaury A, Niolat J, Gogov S, Anak O, Knox J. Record-3: Phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2013, 31:4504. abstract.
12. O'Sullivan CG, Madan RA, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol 2014, 32:1-2.
13. Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001, 24:287-293.
14. Kaufman HL, Wong KK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. The use of registries to improve cancer treatment: a National Database for Patients Treated with Interleukin-2 (IL-2). J Personalized Med 2014, 4:52-64.
15. Lowder JN, Aung S, Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA. High-dose interleukin-2 registry: PROCLAIM: Modern data on toxicities and outcomes [abstract]. J Clin Oncol 2014, 4:430. abstract.
16. Wong KK, Daniels GA, Kaufman HL, McDermott DF, Morse MA, Aung S, Lowder JN. High dose interleukin-2 registry, PROCLAIM, higher center-specific IL-2 dose density correlated with higher response rates [abstract]. J Immunol Ther Cancer 2013, 1:P67.
17. HD IL-2 database. [http://www.proclaimregistry.com].